PELF

None

FDA approved breast carcinoma adjuvant therapy.

This drug should be coded

None

Fluorinated pyrimidine; antimetabolite. FDA approved uses on basal cell carcinoma, breast cancer, colorectal cancer, gastric cancer, and pancreatic cancer.

Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.

This drug should be coded

None

An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.

This drug should be coded

None

None

None

The pharmacologically active form of folic acid. FDA approved uses as 1st line colorectal carcinoma in combination with 5-FU and to diminish methotrexate toxicity.

This drug should NOT be coded

None

None

None

None

A granulocyte colony-stimulating factor (G-CSF). Adjunct of Ganciclovir therapy; treatment of neutropenia

March 2015: Zarxio is the first biosimilar product approved in the United States. A biosimilar product is a biological product that is based on a showing that it is highly similar to an already-approved biological product, known as a reference product. There are no differences in terms of safety and effectiveness from the reference product (neupogen)

This drug should NOT be coded